X 0 represents the threshold catalytic activity below which clinical toxicity is experienced. For example, when X 0 = 10%, it is assumed that 10% of the population exhibits a catalytic activity indicative of clinical toxicity.
Comparative toxicity risk between the population A and the population B is calculated by the ratio of the number of individuals who display a slow catalytic activity below X 0 in population B (slower activity) vs population A (faster activity). Note that even a small 0.1 SD difference in mean catalytic activity between the two populations may be reflected by a 29% increase in risk for toxicity in population B when the X 0 is set at 1%. Splus 4.5 (MathSoft, WA, USA) was used to evaluate the normal and inverse normal cumulative distribution functions and the area under the curves.
The main purpose of the paper by Nebert and Menon seems to advise governments not to mandate a routine inclusion of ethnic minorities in all clinical studies. The paper rightly calls for scientific reasoning in all such decisions; any knowledge of established, particular allele frequencies may produce a better choice between populations than selection simply by ethnicity. However, the inclusion of Reply to Kalow 1 Kalow, Ozdemir and Tothfalusi 2 express concern about our statement, 'Pharmacogenetic differences can be 10-to more than 40-fold between individuals within an ethnic group, while the mean variation between ethnic groups is rarely more than 2-to 3-fold; this observation is the hallmark of complex (or multifactorial) traits.' They go on to say, 'This is a crucial argument www.nature.com/tpj an ethnic minority in a clinical study may reveal information on the frequency of an unknown genetic variant which affects a drug response; such information can be of clinical importance and may increase the safety of some members of that ethnic population. This fact favors the inclusion of ethnic minorities in clinical studies.
It is important to note that differences in population means may in their review, . . .' Actually, this was not intended to be 'a crucial argument,' and what follows is our attempt to clarify our intentions in that invited 'Perspectives' article.
Later, Kalow and coworkers 2 say, 'The main purpose of the paper by Nebert and Menon seems to advise governments not to mandate a routine inclusion of ethnic minorities in all clinical studies.' The subject of our article was primarily concerned with the public's perception of 'race,' how underestimate the clinically important changes at the edges of a population. Furthermore, the more rare a pharmacological trait is, the more it will be influenced by changes in population means.
incredibly admixed almost all human populations are in the present day, and how alleles of the three major races have diverged.
Kalow et al 2 state further, '(this observation) is also valid when there are cases of monogenically controlled drug responses,' and proceed to discuss the 'Edge Effect'-which was originally presented as Figure 3 in the Kalow and Bertilsson 1994 review. 3 We completely agree with their central tenet that the proportion of subjects 'on the edge' can be strongly influenced by the population mean, even if the population means differ only moderately; in fact, one of us (DWN) uses this 'Edge Effect concept' as a slide in several (pharmacology, pharmacy, occupational medicine) teaching sessions with students each year.
The concept of a 'monogenically controlled drug response' or a 'monogenic inborn-error-of-metabolism,' ' and reasons for this inconsistency include thresholds for protein function, modifier genes, and systems dynamics, ie no single-gene product is solely causal for the phenotype in any system, and more than one gene product will influence the activity and regulation of each and every system. This concept can certainly be extended to include all the cases of socalled 'monogenic' pharmacogenetic disorders, such as, for example, the NAT2 and CYP2D6 polymorphisms. In the original clinical study of plasma concentrations of isoniazid to separate autosomal recessive 'slow' acetylators from 'rapid' acetylators, 5 267 patients were given isoniazid (9.8 mg kg Ϫ1 body weight), urine was collected 6 h later, and subjects ranging from 2.5 g ml Ϫ1 to 12 g ml Ϫ1 (Ͼ4-fold
The Pharmacogenomics Journal difference) were all classified as having the slow-acetylator trait. In the original study of metabolic ratios (urinary debrisoquine divided by hydroxydebrisoquine) to distinguish the 'efficient-metabolizer' (EM) from the 'poor-metabolizer' (PM) phenotype, 6 log 10 values from Ϫ1.7 to ϩ1.0 (ෂ240-fold difference) were all lumped together as having the EM trait. Thresholds for gene product function, modifier genes, and systems dynamics undoubtedly contribute to the range and variability of values seen in these predominantly 'monogenic' disorders. 4, 7 Lastly, Kalow et al 2 say, 'However, the inclusion of an ethnic minority in a clinical study may reveal information on the frequency of an unknown genetic variant which affects a drug response; such information can be of clinical importance and may increase the safety of some members of that ethnic population. ' We agree completely, and we presented situations in our review 1 where clinical stratification is crucial to the outcome of the study, as well as instances where genetic admixture makes ethnic stratification meaningless. One of the best cases of ethnic differences having clinical pharmacogenetic importance is found in CYP2C19-which metabolizes Smephenytoin, omeprazole, diazepam, propranolol, citalopram, proguanil/ chloroguanil, imipramine, amitryptyline, mephobarbital, hexobarbital, and many other drugs. 8 The CYP2C19 PM patient requires a lower dose of these drugs for efficacy than the CYP2C19 EM patient, and the PM patient is more prone than the EM person to toxicity, if both are given the 'recommended' prescribed dose of such pharmaceuticals, and especially if the drug has a narrow therapeutic index. Two reference ('wild-type') EM alleles (CYP2C19*1A, *1B) and nine PM mutant alleles have now been described; all nine of these variants exhibit little or no enzyme activity. 9 The frequency of CYP2C19 PM individuals (having two autosomal recessive alleles) ranges between 2% and 5% in Caucasians and between 13% and 23% in Asians. More specifically, the frequency of the CYP2C19*2A and *2B alleles (responsible for splicing defects) is 2-5% in Caucasians, yet 20-30% in Asians; the frequency of the CYP2C19* 3 allele (premature stop codon) is exclusively Asian and ranges between 13% and 23%. 8 This is an excellent example in which the physician must be much more careful in prescribing any of the drugs in the 'CYP2C19 battery' for a Chinese patient than for a Caucasian patient. Similarly, pharmaceutical companies in China must regard the importance of the CYP2C19 polymorphism in the Chinese population much more so than companies in predominantly Caucasian countries. 
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